

Status: Currently Official on 17-Feb-2025

Official Date: Official as of 01-May-2020

Document Type: USP Monographs

DocId: GUID-6B335FC2-CC1A-4CD7-AD5D-D6CAC65475D1_6_en-US


DOI: https://doi.org/10.31003/USPNF_M83650_06_01

DOI Ref: 7e388

© 2025 USPC

Do not distribute

Timolol Maleate

 $C_{13}H_{24}N_4O_3S \cdot C_4H_4O_4$

432.49

2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-[(4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy]-, (S)-, (Z)-2-butenedioate (1:1) (salt);
 (-)-1-(tert-Butylamino)-3-[(4-morpholin-4-yl)-1,2,5-thiadiazol-3-yl]oxy]-2-propanol maleate (1:1) (salt) CAS RN®: 26921-17-5; UNII: P8Y54F701R.

DEFINITION

Timolol Maleate contains NLT 98.0% and NMT 102.0% of timolol maleate ($C_{13}H_{24}N_4O_3S \cdot C_4H_4O_4$), calculated on the dried basis.

IDENTIFICATION

Change to read:

- A. **A. ▲SPECTROSCOPIC IDENTIFICATION TESTS (197), Infrared Spectroscopy:** 197M or 197A▲ (CN 1-May-2020)
- B. The retention time of the timolol peak of the *Sample solution* corresponds to that of the *System suitability solution*, as obtained in the *Enantiomeric Purity* test.

ASSAY

• PROCEDURE

Solution A: Dilute 0.5 mL of [trifluoroacetic acid](#) with [water](#) to 1 L.

Solution B: Dilute 0.5 mL of [trifluoroacetic acid](#) with [acetonitrile](#) to 1 L.

Mobile phase: See [Table 1](#).

Table 1

Time (min)	Solution A (%)	Solution B (%)
0	84	16
2.4	84	16
8	20	80
8.1	84	16
11	84	16

Diluent: [Methanol](#) and [water](#) (60:40)

System suitability solution: 100 µg/mL of [USP Timolol Maleate RS](#) and 10 µg/mL of [USP Timolol Related Compound D RS](#) in *Diluent*

Standard solution: 100 µg/mL of [USP Timolol Maleate RS](#) in *Diluent*

Sample solution: 100 µg/mL of Timolol Maleate in *Diluent*

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC**Detector:** UV 295 nm**Column:** 2.1-mm × 10-cm; 2.6-µm packing [L1](#)**Autosampler temperature:** 4°**Flow rate:** 0.4 mL/min**Injection volume:** 2.5 µL**System suitability****Samples:** System suitability solution and Standard solution**Suitability requirements****Resolution:** NLT 2 between timolol and timolol related compound D, System suitability solution**Tailing factor:** NMT 2.0, Standard solution**Relative standard deviation:** NMT 0.73%, Standard solution**Analysis****Samples:** Standard solution and Sample solutionCalculate the percentage of timolol maleate ($C_{13}H_{24}N_4O_3S \cdot C_4H_4O_4$) in the portion of Timolol Maleate taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

 r_U = peak response of timolol from the Sample solution r_S = peak response of timolol from the Standard solution C_S = concentration of [USP Timolol Maleate RS](#) in the Standard solution (µg/mL) C_U = concentration of Timolol Maleate in the Sample solution (µg/mL)**Acceptance criteria:** 98.0%–102.0% on the dried basis**IMPURITIES**

- [RESIDUE ON IGNITION \(281\)](#): NMT 0.1%

Change to read:

- [ORGANIC IMPURITIES](#)

Solution A, Solution B, Mobile phase, Diluent, and Chromatographic system: Proceed as directed in the Assay.**▲Sensitivity solution:** 0.5 µg/mL of [USP Timolol Maleate RS](#) in Diluent▲ (USP 1-Dec-2019)**System suitability solution:** 100 µg/mL each of [USP Timolol Maleate RS](#), [USP Timolol Related Compound B RS](#), [USP Timolol Related Compound C RS](#), [USP Timolol Related Compound D RS](#), [USP Timolol Related Compound E RS](#), and [USP Timolol Related Compound F RS](#) in Diluent. [NOTE—Prepare fresh and analyze immediately as [USP Timolol Related Compound E RS](#) degrades rapidly.]**Standard solution:** 1 µg/mL of [USP Timolol Maleate RS](#) and 4 µg/mL each of [USP Timolol Related Compound B RS](#), [USP Timolol Related Compound C RS](#), [USP Timolol Related Compound D RS](#), [USP Timolol Related Compound E RS](#), and [USP Timolol Related Compound F RS](#) in Diluent. Sonicate if needed for 0.5 min.**Sample solution:** 1 mg/mL of Timolol Maleate in Diluent**System suitability****Samples:** ▲Sensitivity solution,▲ (USP 1-Dec-2019) System suitability solution, and Standard solution**Suitability requirements****Resolution:** NLT 2.0 between timolol and timolol related compound D, System suitability solution**Relative standard deviation:** NMT 4.0% for timolol, Standard solution**▲Signal-to-noise ratio:** NLT 10 for timolol, Sensitivity solution▲ (USP 1-Dec-2019)**Analysis****Samples:** Standard solution and Sample solution

▲Calculate the percentage of timolol maleate ester (free base of timolol related compound E) in the portion of Timolol Maleate taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$$

 r_U = peak response of timolol maleate ester from the Sample solution r_S = peak response of timolol maleate ester from the Standard solution

C_s = concentration of [USP Timolol Related Compound E RS](#) in the *Standard solution* ($\mu\text{g/mL}$)

C_u = concentration of Timolol Maleate in the *Sample solution* ($\mu\text{g/mL}$)

M_{r1} = molecular weight of timolol maleate ester, 414.48

M_{r2} = molecular weight of timolol related compound E, 530.55

Calculate the percentage of timolol bisthiadiazol analog (free base of timolol related compound C) in the portion of Timolol Maleate taken:

$$\text{Result} = (r_u/r_s) \times (C_s/C_u) \times (M_{r1}/M_{r2}) \times 100$$

r_u = peak response of timolol bisthiadiazol from the *Sample solution*

r_s = peak response of timolol bisthiadiazol from the *Standard solution*

C_s = concentration of [USP Timolol Related Compound C RS](#) in the *Standard solution* ($\mu\text{g/mL}$)

C_u = concentration of Timolol Maleate in the *Sample solution* ($\mu\text{g/mL}$)

M_{r1} = molecular weight of timolol bisthiadiazol, 485.62

M_{r2} = molecular weight of timolol related compound C, 601.69▲ (USP 1-Dec-2019)

Calculate the percentage of ▲timolol related compound B, D, or F▲ (USP 1-Dec-2019) in the portion of Timolol Maleate taken:

$$\text{Result} = (r_u/r_s) \times (C_s/C_u) \times 100$$

r_u = peak response of ▲timolol related compound B, D, or F▲ (USP 1-Dec-2019) from the *Sample solution*

r_s = peak response of ▲timolol related compound B, D, or F▲ (USP 1-Dec-2019) from the *Standard solution*

C_s = concentration of ▲[USP Timolol Related Compound B RS](#), [USP Timolol Related Compound D RS](#), or [USP Timolol Related Compound F RS](#)▲ (USP 1-Dec-2019) in the *Standard solution* ($\mu\text{g/mL}$)

C_u = concentration of Timolol Maleate in the *Sample solution* ($\mu\text{g/mL}$)

Calculate the percentage of any individual unspecified impurity in the portion of Timolol Maleate taken:

$$\text{Result} = (r_u/r_s) \times (C_s/C_u) \times 100$$

r_u = peak response of any individual unspecified impurity from the *Sample solution*

r_s = peak response of timolol from the *Standard solution*

C_s = concentration of [USP Timolol Maleate RS](#) in the *Standard solution* ($\mu\text{g/mL}$)

C_u = concentration of Timolol Maleate in the *Sample solution* ($\mu\text{g/mL}$)

Acceptance criteria: See [Table 2](#). ▲The reporting threshold is 0.05%.▲ (USP 1-Dec-2019)

Table 2

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
Timolol related compound B	0.5	0.4
Timolol related compound D	0.8	0.4

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
Timolol maleate	1.0	—
▲Timolol maleate ester ^a ▲ (USP 1-Dec-2019)	1.4	0.4
▲Timolol bisthiadiazol analog ^b ▲ (USP 1-Dec-2019)	1.8	0.4
Timolol related compound F	2.0	0.4
Any individual unspecified impurity	—	0.10
▲Total impurities▲ (USP 1-Dec-2019)	—	1.0

^a (S)-3-(tert-Butylamino)-1-(4-morpholino-1,2,5-thiadiazol-3-yloxy)propan-2-yl hydrogen maleate.

^b N-(tert-Butyl)-2,3-bis(4-morpholino-1,2,5-thiadiazol-3-yloxy)propan-1-amine.▲ (USP 1-Dec-2019)

Change to read:

- ENANTIOMERIC PURITY

Prepare all solutions in low-actinic glassware protected from light.

Mobile phase: [Diethylamine, 2-propanol](#), and [hexane](#) (2:40:960)

Diluent: [Methylene chloride](#) and [2-propanol](#) (25:75)

System suitability solution: 0.03 mg/mL each of [USP Timolol Maleate RS](#) and [USP Timolol Related Compound A RS](#) in *Diluent*

Standard solution: 0.03 mg/mL of [USP Timolol Related Compound A RS](#) in *Diluent*

Sample solution: 3 mg/mL of Timolol Maleate in *Diluent*

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 297 nm

Column: 4.6-mm × 25-cm; 5-μm packing [L40](#)

Flow rate: 1 mL/min

Injection volume: 5 μL

System suitability

Samples: System suitability solution ▲and Standard solution▲ (USP 1-Dec-2019)

Suitability requirements

Resolution: NLT 4.0 between the timolol related compound A and timolol peaks, System suitability solution

Relative standard deviation: NMT 1.5% for ▲the timolol related compound A peak, Standard solution▲ (USP 1-Dec-2019)

Signal-to-noise ratio: NLT 10 for the timolol related compound A peak, ▲Standard solution▲ (USP 1-Dec-2019)

Analysis

Samples: Standard solution and Sample solution

Calculate the percentage of timolol related compound A in the portion of Timolol Maleate taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of timolol related compound A from the *Sample solution*

r_S = peak response of timolol related compound A from the *Standard solution*

C_S = concentration of [USP Timolol Related Compound A RS](#) in the *Standard solution* (mg/mL)

C_U = concentration of Timolol Maleate in the *Sample solution* (mg/mL)


Acceptance criteria: NMT 1.0%

SPECIFIC TESTS• [pH \(791\)](#)**Sample solution:** 20 mg/mL of Timolol Maleate in [water](#)**Acceptance criteria:** 3.8–4.3• [Loss on Drying \(731\)](#)**Analysis:** Dry under vacuum at 100° to constant weight.**Acceptance criteria:** NMT 0.5%**ADDITIONAL REQUIREMENTS****Change to read:**

- **PACKAGING AND STORAGE:** Preserve in well-closed containers, ▲protected from light.▲ (USP 1-Dec-2019)

• [USP Reference Standards \(11\)](#)[USP Timolol Maleate RS](#)[USP Timolol Related Compound A RS](#)


(R)-1-(tert-Butylamino)-3-(4-morpholino-1,2,5-thiadiazol-3-yloxy)propan-2-ol maleate.

[USP Timolol Related Compound B RS](#)


3-(tert-Butylamino)-2-(4-morpholino-1,2,5-thiadiazol-3-yloxy)propan-1-ol.

[USP Timolol Related Compound C RS](#)


N-(tert-Butyl)-2,3-bis(4-morpholino-1,2,5-thiadiazol-3-yloxy)propan-1-amine maleate.

[USP Timolol Related Compound D RS](#)


4-Morpholino-1,2,5-thiadiazol-3-ol.

[USP Timolol Related Compound E RS](#)

(S, Z)-4-((1-(tert-Butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]propan-2-yl)oxy)-4-oxobut-2-enoic acid maleate salt (1:1).

[USP Timolol Related Compound F RS](#)

3-Chloro-4-morpholino-1,2,5-thiadiazol.

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
TIMOLOL MALEATE	Documentary Standards Support	SM22020 Small Molecules 2
REFERENCE STANDARD SUPPORT	RS Technical Services RSTECH@usp.org	SM22020 Small Molecules 2

Chromatographic Database Information: [Chromatographic Database](#)**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. PF 44(5)

Current DocID: [GUID-6B335FC2-CC1A-4CD7-AD5D-D6CAC65475D1_6_en-US](#)**DOI:** https://doi.org/10.31003/USPNF_M83650_06_01**DOI ref:** [7e388](#)